Viking Therapeutics, Biomea Fusion, and Ardelyx Inc. Lead Biotech Stock Gains with Promising Clinical Results
• Viking Therapeutics' stock surged following positive Phase 1 trial results for VK2735, a potential treatment for metabolic disorders.
• Biomea Fusion saw its stock nearly double after announcing promising initial results from a Phase 2 clinical trial for a type 2 diabetes drug.
• Ardelyx Inc. experienced a stock increase driven by strong sales of its gastrointestinal disease medication, Ibsrela, and positive prescription growth forecasts.
© Copyright 2025. All Rights Reserved by MedPath